Analyst Reco.

23-02-28 HC Wainwright Initiates Magenta Therapeutics at Neutral MT
23-01-26 BTIG Downgrades Magenta Therapeutics to Neutral From Buy MT
23-01-26 Cowen Downgrades Magenta Therapeutics to Market Perform From Outperform MT
23-01-26 Wedbush Downgrades Magenta Therapeutics to Neutral From Outperform on MGTA-117 Safety Issues, Lowers Price Targe to $1 From $3 MT
22-12-21 BTIG Lowers Price Target on Magenta Therapeutics to $3 From $6, Maintains Buy Rating MT
22-12-20 Wedbush Adjusts Magenta Therapeutics Price Target to $3 From $6, Maintains Outperform Rating MT
22-08-25 Goldman Sachs Downgrades Magenta Therapeutics to Neutral From Buy, Maintains $2 Price Target MT
22-05-24 Goldman Sachs Adjusts Price Target for Magenta Therapeutics to $2 From $3, Keeps Buy Rating MT
22-05-16 Wedbush Adjusts Magenta Therapeutics Price Target to $6 From $7, Maintains Outperform Rating MT
22-04-18 Mizuho Securities Adjusts Magenta Therapeutics' Price Target to $8 From $17, Reiterates Buy Rating MT
22-04-18 BTIG Adjusts Magenta Therapeutics' Price Target to $6 From $10, Reiterates Buy Rating MT
22-04-14 Wedbush Adjusts Magenta Therapeutics Price Target to $7 From $9, Maintains Outperform Rating MT
22-03-08 Wedbush Adjusts Magenta Therapeutics Price Target to $9 From $14, Maintains Outperform Rating MT
22-01-24 B. Riley Lowers Magenta Therapeutics' Price Target to $6 from $13 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
22-01-11 Wedbush Trims Magenta Therapeutics' Price Target to $14 From $15, Keeps Outperform Rating MT
22-01-06 Goldman Sachs Lifts Magenta Therapeutics to Buy From Neutral, Price Target to $8 From $7 MT
21-11-08 B. Riley Lowers Magenta Therapeutics' PT to $13 from $19 on Lower Peak Sales for MGTA-145, Keeps Buy Rating MT
21-11-04 Wedbush Adjusts Price Target for Magenta Therapeutics to $15 From $20, Maintains Outperform Rating MT
21-08-03 Analyst recommendations: Applied Industrials, Fastenal, Meggit, Planet Fitness, Krispy Kreme... Zonebourse
21-08-03 MAGENTA THERAPEUTICS : JPMorgan Cuts Magenta Therapeutics to Neutral From Overweight, Price Target to $7 From $16 MT
21-07-22 MAGENTA THERAPEUTICS : B. Riley Lowers Magenta Therapeutics' PT to $19 from $21, Updates Model due to Potential Clinical Trial Delay; Keeps Buy Rating MT
21-07-21 MAGENTA THERAPEUTICS : Wedbush Adjusts Price Target on Magenta Therapeutics to $20 From $22, Keeps Outperform Rating MT
21-06-29 MAGENTA THERAPEUTICS : Cantor Fitzgerald Starts Magenta Therapeutics at Overweight With $20 Price Target MT
21-06-15 MAGENTA THERAPEUTICS : BTIG Starts Magenta Therapeutics at Buy With $20 Price Target MT
21-05-18 MAGENTA THERAPEUTICS : B. Riley Starts Magenta Therapeutics at Buy with $21 Price Target MT
No results for this search